Invivyd

Contributing Author

Recent Articles by Invivyd

Sep-24	Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors IVVD GlobeNewswire
Sep-17	Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer IVVD GlobeNewswire
Sep-04	SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025 IVVD GlobeNewswire
Aug-27	Invivyd to Participate in Upcoming Investor Conferences IVVD GlobeNewswire
Aug-22	Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Shares IVVD GlobeNewswire
Aug-20	Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants IVVD GlobeNewswire
Aug-20	Invivyd Announces Proposed Public Offering of Common Stock IVVD GlobeNewswire
Aug-18	Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG ("Stratus") IVVD GlobeNewswire
Aug-14	Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights IVVD GlobeNewswire
Aug-14	Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19 IVVD GlobeNewswire
Jul-23	Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome IVVD GlobeNewswire
Jul-21	National Comprehensive Cancer Network (NCCN) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population IVVD GlobeNewswire
Jul-02	Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome IVVD GlobeNewswire
Jun-26	Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection IVVD GlobeNewswire
May-27	Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus IVVD GlobeNewswire
May-23	Invivyd Announces Inclusion of PEMGARDA (pemivibart) in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas IVVD GlobeNewswire
May-21	Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19 IVVD GlobeNewswire
May-15	Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights IVVD GlobeNewswire
May-14	Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy IVVD GlobeNewswire
May-13	Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference IVVD GlobeNewswire
May-12	Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles IVVD GlobeNewswire
May-08	Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025 IVVD GlobeNewswire

Invivyd

Recent Articles by Invivyd

Upgrade your FINVIZ experience